NasdaqGM · Biotechnology

Silence Therapeutics (SLN)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+148.7%

$33.00 average target

$13.27+0.10 (+0.8%)Latest market snapshot · Yahoo Finance

Market cap$824.8M

Cash$72.1M

Quarterly burn$15.6M

Pipeline assets3

Short float5.1%

Clinical portfolio

Silence Therapeutics Drug Pipeline

Showing 0 of 3

Pipeline data is not currently available

The page remains usable with the verified company and catalyst data already on file.

Continue with BioPharma ProUnlock 3 additional programs and complete development details.

Unlock Pro

Upcoming milestones

SLN Catalyst Timeline

0 currently tracked

Dated catalysts is not currently available

The page remains usable with the verified company and catalyst data already on file.

Company profile

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.